Chimpanzee adenoviral vectors as vaccines – challenges to move the technology into the fast lane

ABSTRACT Introduction: In recent years, replication-defective chimpanzee-derived adenoviruses have been extensively evaluated as genetic vaccines. These vectors share desirable properties with human adenoviruses like the broad tissue tropism and the ease of large-scale manufacturing. Additionally, chimpanzee adenoviruses have the advantage to overcome the negative impact of pre-existing anti-human adenovirus immunity. Areas covered: Here the authors review current pre-clinical research and clinical trials that utilize chimpanzee-derived adenoviral vectors as vaccines. A wealth of studies are ongoing to evaluate different vector backbones and administration routes with the aim of improving immune responses. The challenges associated with the identification of an optimal chimpanzee vector and immunization strategies for different immunological outcomes will be discussed. Expert commentary: The demonstration that chimpanzee adenoviruses can be safely used in humans has paved the way to the use of a whole new array of vectors of different serotypes. However, so far no predictive signature of vector immunity in humans has been identified. The high magnitude of T cell responses elicited by chimpanzee adenoviruses has allowed dissecting the qualitative aspects that may be important for protective immunity. Ultimately, only the results from the most clinically advanced products will help establish the efficacy of the vaccine vector platform in the field of disease prevention.

[1]  J. Mascola,et al.  Chimpanzee Adenovirus Vector Ebola Vaccine , 2017, The New England journal of medicine.

[2]  R. Cortese,et al.  Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  M. Roederer,et al.  Unique cellular and humoral immunogenicity profiles generated by aerosol, intranasal, or parenteral vaccination in rhesus macaques. , 2017, Vaccine.

[4]  H. Ertl.  Viral vectors as vaccine carriers. , 2016, Current opinion in virology.

[5]  T. Fujiwara,et al.  Enhanced Oncolytic Activities of the Telomerase-Specific Replication-Competent Adenovirus Expressing Short-Hairpin RNA against Dicer , 2016, Molecular Cancer Therapeutics.

[6]  Chao Zhang,et al.  Chimpanzee adenovirus vector-based avian influenza vaccine completely protects mice against lethal challenge of H5N1. , 2016, Vaccine.

[7]  A. Iwasaki.  Exploiting Mucosal Immunity for Antiviral Vaccines. , 2016, Annual review of immunology.

[8]  M. Altfeld,et al.  Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. , 2016, The New England journal of medicine.

[9]  F. Spertini,et al.  Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. , 2016, The Lancet. Infectious diseases.

[10]  V. Nene,et al.  Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever , 2016, Scientific Reports.

[11]  James D. Campbell,et al.  Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial , 2016, The Lancet. Infectious diseases.

[12]  H. McShane,et al.  Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A , 2015, Vaccine.

[13]  Mark M. Davis,et al.  Adenoviral Vector Vaccination Induces a Conserved Program of CD8+ T Cell Memory Differentiation in Mouse and Man , 2015, Cell reports.

[14]  M. Havenga,et al.  Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5–based Constructs , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  John-Arne Røttingen,et al.  Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial , 2015, The Lancet.

[16]  A. Giuliani,et al.  Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections , 2015, Science Translational Medicine.

[17]  Andrew J. Pollard,et al.  Chimpanzee adenovirus– and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults , 2015, Science Translational Medicine.

[18]  M. Jeyanathan,et al.  Mucosal immunity and novel tuberculosis vaccine strategies: route of immunisation-determined T-cell homing to restricted lung mucosal compartments , 2015, European Respiratory Review.

[19]  T. Kanneganti,et al.  Inflammasome control of viral infection. , 2015, Current opinion in virology.

[20]  A. Nicosia,et al.  Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults , 2015, Science Translational Medicine.

[21]  H. Ertl,et al.  Novel chimpanzee adenovirus-vectored respiratory mucosal tuberculosis vaccine: overcoming local anti-human adenovirus immunity for potent TB protection , 2015, Mucosal Immunology.

[22]  Daniel E. Zak,et al.  Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling. , 2015, The Journal of clinical investigation.

[23]  A. Hill,et al.  The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species , 2015, Vaccine.

[24]  Edward Wright,et al.  A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. , 2015, The New England journal of medicine.

[25]  A. Nicosia,et al.  A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and with MVA CS , 2014, PloS one.

[26]  B. Korber,et al.  Construction and Evaluation of Novel Rhesus Monkey Adenovirus Vaccine Vectors , 2014, Journal of Virology.

[27]  Mark M. Davis,et al.  A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory , 2014, Science Translational Medicine.

[28]  R. Cortese,et al.  Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals , 2014, The Journal of infectious diseases.

[29]  Mario Roederer,et al.  Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge , 2014, Nature Medicine.

[30]  A. Nicosia,et al.  Combining Viral Vectored and Protein-in-adjuvant Vaccines Against the Blood-stage Malaria Antigen AMA1: Report on a Phase 1a Clinical Trial , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[31]  Gleb Mironov,et al.  Carbohydrate-Based Ice Recrystallization Inhibitors Increase Infectivity and Thermostability of Viral Vectors , 2014, Scientific Reports.

[32]  T. Hanke,et al.  Safety and Tolerability of Conserved Region Vaccines Vectored by Plasmid DNA, Simian Adenovirus and Modified Vaccinia Virus Ankara Administered to Human Immunodeficiency Virus Type 1-Uninfected Adults in a Randomized, Single-Blind Phase I Trial , 2014, PloS one.

[33]  A. Folgori,et al.  Enhanced Vaccine-Induced CD8+ T Cell Responses to Malaria Antigen ME-TRAP by Fusion to MHC Class II Invariant Chain , 2014, PloS one.

[34]  T. Lawrence,et al.  Dendritic cell maturation: functional specialization through signaling specificity and transcriptional programming , 2014, The EMBO journal.

[35]  A. Folgori,et al.  Fusion of HCV nonstructural antigen to MHC class II-associated invariant chain enhances T-cell responses induced by vectored vaccines in nonhuman primates. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[36]  I. Melero,et al.  Orchestrating immune check-point blockade for cancer immunotherapy in combinations. , 2014, Current opinion in immunology.

[37]  B. Jia,et al.  The prevalence of neutralising antibodies to chimpanzee adenovirus type 6 and type 7 in healthy adult volunteers, patients with chronic hepatitis B and patients with primary hepatocellular carcinoma in China , 2014, Archives of Virology.

[38]  C. Rupprecht,et al.  Protection of non-human primates against rabies with an adenovirus recombinant vaccine. , 2014, Virology.

[39]  Lucy Dorrell,et al.  Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[40]  A. Hill,et al.  Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A Antigens , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[41]  A. Hill,et al.  Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley Fever vaccine in mice , 2013, Virology Journal.

[42]  A. Folgori,et al.  Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation , 2013, Nature Communications.

[43]  E. Delwart,et al.  The Viruses of Wild Pigeon Droppings , 2013, PloS one.

[44]  Adrian V. S. Hill,et al.  Dry-Coated Live Viral Vector Vaccines Delivered by Nanopatch Microprojections Retain Long-Term Thermostability and Induce Transgene-Specific T Cell Responses in Mice , 2013, PloS one.

[45]  D. Montefiori,et al.  Comparison of Systemic and Mucosal Immunization with Helper-Dependent Adenoviruses for Vaccination against Mucosal Challenge with SHIV , 2013, PloS one.

[46]  B. Jia,et al.  Seroprevalence of neutralizing antibodies to human adenoviruses type‐5 and type‐26 and chimpanzee adenovirus type‐68 in healthy Chinese adults , 2013, Journal of medical virology.

[47]  Kylie M. Quinn,et al.  Comparative Analysis of the Magnitude, Quality, Phenotype, and Protective Capacity of Simian Immunodeficiency Virus Gag-Specific CD8+ T Cells following Human-, Simian-, and Chimpanzee-Derived Recombinant Adenoviral Vector Immunization , 2013, The Journal of Immunology.

[48]  R. Cortese,et al.  Vaccination to Conserved Influenza Antigens in Mice Using a Novel Simian Adenovirus Vector, PanAd3, Derived from the Bonobo Pan paniscus , 2013, PloS one.

[49]  R. Cortese,et al.  ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[50]  Daniel E. Zak,et al.  Merck Ad5/HIV induces broad innate immune activation that predicts CD8+ T-cell responses but is attenuated by preexisting Ad5 immunity , 2012, Proceedings of the National Academy of Sciences.

[51]  K. Bojang,et al.  A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity , 2012, PloS one.

[52]  D. Barouch,et al.  Vaccination with Adenovirus Serotypes 35, 26, and 48 Elicits Higher Levels of Innate Cytokine Responses than Adenovirus Serotype 5 in Rhesus Monkeys , 2012, Journal of Virology.

[53]  R. Cortese,et al.  Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors , 2012, PloS one.

[54]  A. Folgori,et al.  Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector , 2012, The Journal of infectious diseases.

[55]  A. Folgori,et al.  Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species , 2012, Science Translational Medicine.

[56]  A. Folgori,et al.  Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man , 2012, Science Translational Medicine.

[57]  Allan C. deCamp,et al.  Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. , 2012, The Journal of clinical investigation.

[58]  R. Cortese,et al.  Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[59]  R. Koup,et al.  Adenovirus type-35 vectors block human CD4+ T-cell activation via CD46 ligation , 2011, Proceedings of the National Academy of Sciences.

[60]  R. Crystal,et al.  Protective anti-Pseudomonas aeruginosa humoral and cellular mucosal immunity by AdC7-mediated expression of the P. aeruginosa protein OprF. , 2011, Vaccine.

[61]  James M. Wilson,et al.  Creation of a panel of vectors based on ape adenovirus isolates , 2011, The journal of gene medicine.

[62]  M. Betts,et al.  Vaccination with Ad5 Vectors Expands Ad5-Specific CD8+ T Cells without Altering Memory Phenotype or Functionality , 2010, PloS one.

[63]  Mark R. Soboleski,et al.  Single-Dose Mucosal Immunization with a Candidate Universal Influenza Vaccine Provides Rapid Protection from Virulent H5N1, H3N2 and H1N1 Viruses , 2010, PloS one.

[64]  J. Gall,et al.  Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28. , 2010, Vaccine.

[65]  P. Kaleebu,et al.  Adenovirus-Based Vaccines: Comparison of Vectors from Three Species of Adenoviridae , 2010, Journal of Virology.

[66]  D. Kaufman,et al.  Route of Adenovirus-Based HIV-1 Vaccine Delivery Impacts the Phenotype and Trafficking of Vaccine-Elicited CD8+ T Lymphocytes , 2010, Journal of Virology.

[67]  M. Betts,et al.  Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive. , 2010, Vaccine.

[68]  C. Rice,et al.  The Yellow Fever Virus Vaccine Induces a Broad and Polyfunctional Human Memory CD 8 T Cell Response 1 , 2009 .

[69]  S. Nadin-Davis,et al.  Safety studies on an adenovirus recombinant vaccine for rabies (AdRG1.3-ONRAB) in target and non-target species. , 2009, Vaccine.

[70]  R. Cortese,et al.  Prime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Durability and Polyfunctionality of Protective Malaria CD8+ T-Cell Responses , 2009, Infection and Immunity.

[71]  S. McCormack,et al.  Faculty Opinions recommendation of Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. , 2009 .

[72]  J. Plotkin,et al.  Isolation and Characterization of Adenoviruses Persistently Shed from the Gastrointestinal Tract of Non-Human Primates , 2009, PLoS pathogens.

[73]  A. Nicosia,et al.  Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. , 2009, Vaccine.

[74]  M. Betts,et al.  Baseline Ad5 serostatus does not predict Ad5-HIV vaccine-induced expansion of Ad-specific CD4+ T-cells , 2009, Nature Medicine.

[75]  N. Arnberg.  Adenovirus receptors: implications for tropism, treatment and targeting , 2009, Reviews in medical virology.

[76]  Lili Wang,et al.  Host Immune Responses to Chronic Adenovirus Infections in Human and Nonhuman Primates , 2008, Journal of Virology.

[77]  Devan V Mehrotra,et al.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial , 2008, The Lancet.

[78]  J. Harty,et al.  Single‐dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei , 2008, European journal of immunology.

[79]  C. Elson,et al.  Perspectives on Mucosal Vaccines: Is Mucosal Tolerance a Barrier?1 , 2007, The Journal of Immunology.

[80]  Malcolm K. Brenner,et al.  Identification of Hexon-Specific CD4 and CD8 T-Cell Epitopes for Vaccine and Immunotherapy , 2007, Journal of Virology.

[81]  E. Wherry,et al.  Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. , 2007, Blood.

[82]  S. Hensley,et al.  A CD46-binding chimpanzee adenovirus vector as a vaccine carrier. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[83]  B. Williams,et al.  Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[84]  Z. Xiang,et al.  A chimpanzee-origin adenovirus vector expressing the rabies virus glycoprotein as an oral vaccine against inhalation infection with rabies virus. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[85]  P. Jeena,et al.  Age Dependence of Adenovirus-Specific Neutralizing Antibody Titers in Individuals from Sub-Saharan Africa , 2006, Journal of Clinical Microbiology.

[86]  S. Ellenberg,et al.  Chimpanzee Adenovirus Antibodies in Humans, Sub-Saharan Africa , 2006, Emerging infectious diseases.

[87]  G. Kobinger,et al.  Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. , 2006, Virology.

[88]  H. Ertl,et al.  Chimpanzee-origin adenovirus vectors as vaccine carriers , 2006, Gene Therapy.

[89]  K. Ebner,et al.  Comparative Sequence Analysis of the Hexon Gene in the Entire Spectrum of Human Adenovirus Serotypes: Phylogenetic, Taxonomic, and Clinical Implications , 2005, Journal of Virology.

[90]  C. Elmets,et al.  Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. , 2005, Vaccine.

[91]  Hildegund C.J. Ertl,et al.  Adenoviruses as vaccine vectors , 2004, Molecular Therapy.

[92]  Z. Xiang,et al.  Human Immunodeficiency Virus Type 1-Specific Immune Responses in Primates upon Sequential Immunization with Adenoviral Vaccine Carriers of Human and Simian Serotypes , 2004, Journal of Virology.

[93]  M. Lock,et al.  Characterization of a family of chimpanzee adenoviruses and development of molecular clones for gene transfer vectors. , 2004, Human gene therapy.

[94]  M. Bachmann,et al.  The Human Membrane Cofactor CD46 Is a Receptor for Species B Adenovirus Serotype 3 , 2004, Journal of Virology.

[95]  S. Kochanek,et al.  Adenoviral vectors for gene transfer and therapy , 2004, The journal of gene medicine.

[96]  G. Cheng,et al.  Toll-like receptors and innate antiviral responses. , 2003, Current opinion in immunology.

[97]  T. Peto,et al.  Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. , 2003, Vaccine.

[98]  James M. Wilson,et al.  Efficient transduction of human monocyte-derived dendritic cells by chimpanzee-derived adenoviral vector. , 2003, Human gene therapy.

[99]  Z. Xiang,et al.  A Simian Replication-Defective Adenoviral Recombinant Vaccine to HIV-1 Gag 1 , 2003, The Journal of Immunology.

[100]  R. M. Burnett,et al.  Replication-Defective Vector Based on a Chimpanzee Adenovirus , 2001, Journal of Virology.

[101]  R. Burger,et al.  Complement activation by recombinant adenoviruses , 2001, Gene Therapy.

[102]  P. Kelley,et al.  Prevalence of antibodies to adenovirus serotypes 4 and 7 among unimmunized US Army trainees: results of a retrospective nationwide seroprevalence survey. , 1998, The Journal of infectious diseases.

[103]  D. Brough,et al.  The Coxsackievirus-Adenovirus Receptor Protein Can Function as a Cellular Attachment Protein for Adenovirus Serotypes from Subgroups A, C, D, E, and F , 1998, Journal of Virology.

[104]  N. Horikoshi,et al.  Blockage by Adenovirus E4orf6 of Transcriptional Activation by the p53 Tumor Suppressor , 1996, Science.

[105]  G. Nemerow,et al.  Multiple adenovirus serotypes use alpha v integrins for infection , 1994, Journal of virology.

[106]  R. Wigand.  Pitfalls in the identification of adenoviruses. , 1987, Journal of virological methods.

[107]  D. Farber,et al.  Memory CD4 T cells in influenza. , 2015, Current topics in microbiology and immunology.

[108]  D. Brough,et al.  Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[109]  Robyn P. Seipp,et al.  MUCOSAL IMMUNITY AND VACCINES , 2013 .

[110]  Eva K. Lee,et al.  Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans , 2009, Nature Immunology.

[111]  H. Burgert,et al.  Immunomodulatory Functions Encoded by the E3 Transcription Unit of Adenoviruses , 2004, Virus Genes.